The Patented Medicines (Notice of Compliance) Regulations (“PM(NOC)”) provides a link between Canada’s patent and drug approval systems. The Canada-EU Comprehensive Economic and Trade Agreement (“CETA”) calls for significant overhauls to the Canadian patent system. The Canada Gazette recently published proposed amendments to the PM(NOC), as well as proposed Certificate of Supplementary Protection Regulations. Highlights include: early and mandatory case management in PM(NOC) proceedings, a new appeal framework for PM(NOC) decisions, and supplementary protection for patents relating to human drugs. Comments on the proposed regulations must be submitted before 31 July 2017. Read more here and here.
NOT LEGAL ADVICE.
Information made available on this website in any form is for information purposes only. It is not, and should not be taken as legal advice. You should not rely on, or take or fail to take any action, based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Oyen Wiggs Green & Mutala LLP professionals will be pleased to discuss resolutions to specific legal concerns you may have.